Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$105,000.00

Modulation of the endocannabinoid system in mouse models of GRIN1 disorder

EF 2021-22

Résumé
GRIN1 disorder is a neurodevelopmental disorder caused by mutation to the GRIN1 gene. This gene carries the genetic information for the essential subunit of NMDA receptors, which are required for development, learning and memory. Children who have GRIN1 disorder display a range of symptoms of varying severity including autism, intellectual disability, and seizure. This is due to the large number of mutations that can occur across the GRIN1 gene which differentially impact NMDA receptor function. Our lab has developed mouse models harbouring specific GRIN1 variants that display behaviours closely aligned with the patients who carry them. These highly representative models present an opportunity to identify medicines useful for treating GRIN1 disorder. Some of these potential treatments may target the endocannabinoid system, a neuroregulatory system consisting of endogenous cannabinoids, their associated receptors, and enzymes. Alterations in this system have been implicated in other neurodevelopmental disorders and correcting these endocannabinoid imbalances has improved behaviours in corresponding mouse models. We hypothesize that imbalances also occur in GRIN1 disorder as activation of NMDA receptors help facilitate the release of endocannabinoids. Characterization of the endocannabinoid system and the therapeutic potential of modulating it remains unexplored in GRIN1. To do this, we will utilize our GRIN1 patient variant mouse models to characterize the levels of endocannabinoid system components and to study the effect of GRIN1 mutations on NMDA receptor mediated endocannabinoid release. In addition, we will test the effectiveness of drugs that increase endocannabinoid levels to improve the behavioural phenotypes of these mice. In Aim 1, we study endocannabinoid system component levels and signaling in our mouse models. In Aim 2, we assess the ability of pharmacological modulation of the endocannabinoid system to improve altered behaviours in our mouse models.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
458304
Name
Sullivan Megan T
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Modulation of the endocannabinoid system in mouse models of GRIN1 disorder
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Endocannabinoid System; Grin1; Mouse Models; Nmda Receptor
Abstract
GRIN1 disorder is a neurodevelopmental disorder caused by mutation to the GRIN1 gene. This gene carries the genetic information for the essential subunit of NMDA receptors, which are required for development, learning and memory. Children who have GRIN1 disorder display a range of symptoms of varying severity including autism, intellectual disability, and seizure. This is due to the large number of mutations that can occur across the GRIN1 gene which differentially impact NMDA receptor function. Our lab has developed mouse models harbouring specific GRIN1 variants that display behaviours closely aligned with the patients who carry them. These highly representative models present an opportunity to identify medicines useful for treating GRIN1 disorder. Some of these potential treatments may target the endocannabinoid system, a neuroregulatory system consisting of endogenous cannabinoids, their associated receptors, and enzymes. Alterations in this system have been implicated in other neurodevelopmental disorders and correcting these endocannabinoid imbalances has improved behaviours in corresponding mouse models. We hypothesize that imbalances also occur in GRIN1 disorder as activation of NMDA receptors help facilitate the release of endocannabinoids. Characterization of the endocannabinoid system and the therapeutic potential of modulating it remains unexplored in GRIN1. To do this, we will utilize our GRIN1 patient variant mouse models to characterize the levels of endocannabinoid system components and to study the effect of GRIN1 mutations on NMDA receptor mediated endocannabinoid release. In addition, we will test the effectiveness of drugs that increase endocannabinoid levels to improve the behavioural phenotypes of these mice. In Aim 1, we study endocannabinoid system component levels and signaling in our mouse models. In Aim 2, we assess the ability of pharmacological modulation of the endocannabinoid system to improve altered behaviours in our mouse models.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Sullivan, Megan T
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~